Online inquiry

IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3629MR)

This product GTTS-WQ3629MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets FGFR2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000141.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2263
UniProt ID P21802
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3629MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15140MR IVTScrip™ mRNA-Anti-FCGRT, SYNT-001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SYNT-001
GTTS-WQ7903MR IVTScrip™ mRNA-Anti-MAG, GSK-249320(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA GSK-249320
GTTS-WQ852MR IVTScrip™ mRNA-Anti-PRLR, ABBV-176(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-176
GTTS-WQ709MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA A-623
GTTS-WQ14875MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ14401MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ9263MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IMMU-130
GTTS-WQ9492MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA J2898A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW